CDH1 and neoplasm: Additional studies will be required to demonstrate that quantification of hsa-miR-200c-3p expression in patient-derived tumor samples is technically feasible and to survey the frequency distribution of hsa-miR-200c-3p expression and correlation with E-cadherin expression in various cancer types.